focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksERGO.L Regulatory News (ERGO)

  • There is currently no data for ERGO

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Exercise of Share Options and Total Voting Rights

16 Nov 2022 07:00

RNS Number : 5095G
Ergomed plc
16 November 2022
 

 PRESS RELEASE

 

 

Exercise of Share Options and Total Voting Rights

 

 

Guildford, UK - 16 November 2022: Ergomed plc (LSE: ERGO) ("Ergomed" or the "Company") announces that, following an exercise of share options, application has been made to AIM for the admission of 40,000 new ordinary shares of 1p each in the capital of the Company (the "New Ordinary Shares").

 

Admission to trading on AIM of the New Ordinary Shares ("Admission") is expected to occur on 21 November 2022. Following Admission, the New Ordinary Shares will rank pari passu in all respects with the Company's existing ordinary shares.

 

Following Admission, the total number of ordinary shares with voting rights in issue will be 50,128,805. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

 

 

ENDS

 

Enquiries:

 

Ergomed plc Tel: +44 (0) 1483 402 975

Dr Miroslav Reljanović (Executive Chairman)

Richard Barfield (Chief Financial Officer)

Keith Byrne (Senior Vice-President, Capital Markets & Strategy)

Numis   Tel: +44 (0) 20 7260 1000

Freddie Barnfield / Euan Brown (Nominated Adviser)

James Black (Broker)

 

Peel Hunt LLP   Tel: +44 (0) 20 7418 8900

James Steel / Dr Christopher Golden

Consilium Strategic Communications Tel: +44 (0) 20 3709 5700

Chris Gardner / Matthew Neal ergomed@consilium-comms.com

Angela Gray

 

 

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing services business includes an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality clinical research and trial management services under the Ergomed brand (CRO) and mission-critical regulatory compliance and consulting services under the ADAMAS brand. For further information, visit: http://ergomedplc.com.

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCBABFTMTIBBMT
Date   Source Headline
2nd Jun 20234:48 pmRNSTR1 Notification
26th May 20238:38 amRNSNotice of AGM and Annual Report
19th Apr 20237:00 amRNSDirector's Dealing
17th Apr 20237:00 amRNSHolding(s) in Company
13th Apr 20233:27 pmRNSHoldings in Company
3rd Apr 20239:51 amRNSHolding(s) in Company
3rd Apr 20237:00 amRNSTotal Voting Rights
30th Mar 20233:37 pmRNSHolding(s) in Company
21st Mar 20237:00 amRNSErgomed Preliminary Results 2022
17th Mar 202311:39 amRNSHoldings in Company
1st Mar 20237:07 amRNSTotal Voting Rights
16th Feb 20231:44 pmRNSHolding(s) in Company
14th Feb 20237:01 amRNSNotice of Preliminary Results
1st Feb 20237:00 amRNSTotal Voting Rights
25th Jan 20237:00 amRNSJonathan Curtain appointed CFO
25th Jan 20237:00 amRNSErgomed 2022 Trading Update
20th Jan 20235:23 pmRNSHolding(s) in Company
20th Jan 20239:38 amRNSHolding(s) in Company
3rd Jan 20237:00 amRNSTotal Voting Rights and Block Listing Return
5th Dec 20227:00 amRNSDirector Dealings
2nd Dec 20227:00 amRNSJohn Dawson appointed Senior Independent Director
1st Dec 20227:00 amRNSTotal Voting Rights
22nd Nov 20227:00 amRNSExercise of Share Options and Total Voting Rights
21st Nov 202210:46 amEQSErgomed (ERGO): Two key management changes
17th Nov 20227:00 amRNSErgomed Strengthens Executive Management Team
16th Nov 20227:00 amRNSExercise of Share Options and Total Voting Rights
1st Nov 20224:16 pmRNSExercise of Share Options and Total Voting Rights
1st Nov 20227:00 amRNSTotal Voting Rights
20th Oct 20222:09 pmRNSHolding(s) in Company
14th Oct 20224:09 pmRNSHolding(s) in Company
13th Oct 20227:00 amRNSHolding(s) in Company
4th Oct 202212:52 pmEQSErgomed (ERGO): Poised for a strong FY22
3rd Oct 20227:00 amRNSTotal Voting Rights
27th Sep 20227:00 amRNSErgomed Interim results 2022
2nd Sep 20227:00 amRNSHolding(s) in Company
1st Sep 20227:00 amRNSTotal Voting Rights
25th Aug 20227:00 amRNSErgomed Notice of Results
19th Aug 20222:49 pmRNSHolding(s) in Company
1st Aug 20228:10 amEQSErgomed (ERGO): Sustained growth momentum in H122
1st Aug 20227:00 amRNSDirector Dealing
1st Aug 20227:00 amRNSTotal Voting Rights
26th Jul 20227:00 amRNSErgomed H1 2022 Trading Update
1st Jul 20227:00 amRNSTotal Voting Rights and Block Listing Return
10th Jun 202211:21 amRNSResults of 2022 Annual General Meeting
10th Jun 20227:00 amRNSErgomed Annual General Meeting Statement
10th Jun 20227:00 amRNSAnne Whitaker appointed to the Board as NED
1st Jun 20227:00 amRNSErgomed plc Total Voting Rights
13th May 20227:00 amRNSErgomed Notice of AGM and Annual Report
3rd May 20228:49 amRNSErgomed plc Total Voting Rights
28th Apr 20227:01 amEQSErgomed (ERGO): Healthy fundamentals for 2022

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.